Ziresovir for high-risk adults with RSV
Part of Heart & circulation, Infections clinical trials.
This trial tests an antiviral drug called Ziresovir in adults with RSV who have health conditions that make them high-risk, such as lung disease, heart disease, or a weakened immune system. It aims to see if the drug can reduce symptoms like coughing and shortness of breath.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have tested positive for RSV in the last 36 hours.
- You have at least one high-risk condition: chronic lung or heart disease, weakened immune system, another chronic illness, or you are 65 or older.
- You have at least one new or worsening lower respiratory symptom (like cough, wheezing, or shortness of breath) that is moderate to severe.
- Your RSV symptoms started or got worse within the last 5 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if an inhaled interferon solution can help children under 2 years old with a moderate to severe RSV lung infection. It aims to reduce symptoms like cough and trouble breathing.
This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.
This study looks for markers in the blood that can tell how serious an RSV infection might become. If you are hospitalized with RSV and have breathing symptoms, this trial will follow your recovery and test for clues about your illness.
This trial tests whether azithromycin (an antibiotic) can improve outcomes for babies and young children in the ICU who have RSV causing serious breathing problems. It mainly looks at children who start strong breathing support soon after RSV symptoms begin.
This Phase 1/2 study tests an RSV vaccine (BLB-201) in infants and young children. It aims to see how the vaccine works and how safe it is, including in children who already have RSV antibodies or not.
This study tests a medicine called AK0529 for babies and toddlers hospitalized with RSV. It aims to see if the drug helps them recover faster and is safe for this age group.
Hear when a new Respiratory Syncytial Virus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.